Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
3.360
-0.415 (-10.99%)
At close: Dec 5, 2025, 4:00 PM EST
3.340
-0.020 (-0.60%)
After-hours: Dec 5, 2025, 7:40 PM EST
Artiva Biotherapeutics Revenue
In the year 2024, Artiva Biotherapeutics had annual revenue of $251.00K, down -99.25%.
Revenue (ttm)
$251.00K
Revenue Growth
-99.25%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
89
Market Cap
82.47M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ARTV News
- 23 days ago - Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease - GlobeNewsWire
- 23 days ago - Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 weeks ago - Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK® - GlobeNewsWire
- 5 weeks ago - Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November - GlobeNewsWire
- 7 weeks ago - Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update - GlobeNewsWire
- 3 months ago - Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025 - GlobeNewsWire
- 4 months ago - Artiva (ARTV) Q2 Loss Widens 19.7% - The Motley Fool
- 4 months ago - Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights - GlobeNewsWire